Global drugmakers Pfizer and BioNTech said on Wednesday their COVID-19 vaccine candidate is 95 per cent effective, including in people over 65 years of age, a major announcement coming just two days after Moderna said its virus vaccine has an efficacy rate of 94.5 per cent.
Pfizer and BioNTech said they have concluded phase 3 study of their mRNA-based COVID-19 vaccine candidate BNT162b2, meeting all primary efficacy endpoints. Based on current projections, the companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021.
This week, leading biotechnology company Moderna said its COVID-19 vaccine had shown to be 94.5 per cent effective. Earlier this month, Pfizer and Biontech had said their COVID-19 vaccine candidate was found to be more than 90 per cent effective in preventing COVID-19 in participants. (AGENCIES)
Follow our WhatsApp channel
